Daewoong Pharmaceuticals Co., Ltd pursues meaningful work by collaborating with great people, working with autonomy, and choosing opportunities that create shared value for the company, customers, and society. Above all, we are committed to driving real change and innovation through what we do. Establish in 1945, Daewoong Pharmaceuticals is a leading healthcare company in Korea that has achieved consecutive successes in new drug development through constant challenge and innovation. Today, we continue to expand a diverse pipeline and next-generation platform technologies, aiming to develop first-in-class and best-in-class innovative medicines for patients worldwide. Our commitment to global standards is proven by GMP certifications from major regulatory authorities such as the U.S. FDA and EMA, along with ISO certifications that demonstrate our excellence in quality, environmental management, and occupational health and safety systems. At Daewoong, we believe that the growth of our employees fuels the growth of the company. We foster a forward-looking corporate culture by promoting smart work practices, career development, and global talent training programs. Beyond Korea, we strive to become a global healthcare leader by creating new value for healthier lives and better quality of life worldwide.
Daewoong Pharmaceutical の市場拡大を追跡しています
過去 90 日間に 92 件のシグナル。
Daewoong Pharmaceutical の海外展開を競合と比較
Daewoong Pharmaceutical自社バーは比較対象企業間の相対的な規模を示します。
列5| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
 Daewoong Pharmaceutical自社 | 0 | 0 | — | 0 | 0 |
Senior Partnership & Leasing - Bali
求人を見るKuta, Bali, Indonesia · 5か月前
Chief Engineer - Bali
求人を見るKuta, Bali, Indonesia · 5か月前
Cafe Team
求人を見るKuta, Bali, Indonesia · 6か月前
#News 📢 대웅제약 presented integrated model-based research findings on its SGLT-2 inhibitor #Enavogliflozin, at the 2026 PAGE (PAGE - Population Approach Group Europe) conference, a leading European forum in quantitative pharmacology.This study quantitatively elucidated the causal relationship between increased urinary glucose excretion following drug administration and the reduction in glycated hemoglobin (HbA1c), and scientifically demonstrated that the absence of significant pharmacokinetic diff ...
終了Not all long-acting depot platforms are created equal. The key lies in how efficiently a drug can be delivered — in a smaller volume.In Episode 2 of the "Maximizing Therapeutic Potential with CURE®" series, we explore how CURE® achieves industry-leading drug loading to deliver a once-monthly therapeutic dose with up to 4–5× less depot mass than competing platforms.#Daewoong #GLP1 #CURE #platform #obesity #diseases #longactinginjectables ...
終了Small differences in wording can easily lead to misunderstandings in pharmaceutical communication.✍️👩💻Ji Young Yoon from 대웅제약’s Medical Team took on the challenge of bringing clarity to the confusion surrounding UDCA-related scientific messages, which had been spreading across multiple channels during the pandemic. By restructuring the messaging system, she helped ensure that accurate, evidence-based information could be delivered consistently.Curious about her journey? Watch the full video no ...
実施中金融界のリーダーが大熊製薬の烏頌スマート工場を視察し、製薬産業における国民成長基金のイノベーション可能性を探った。
大熊製薬は、Mentolifeブランドで大人向け抗酸化サプリメントと子供向け免疫ブースターの2種類の健康サプリメントを発売しました。
大熊製薬、今年のデジタルヘルスケア売上目標3000億ウォン。統合AIヘルスケアプラットフォームを発表し、全国遠隔健康モニタリングを計画。
認証済みメールと直通電話を解放
無料 · カード不要
Daewoong Pharmaceutical の事業、市場、成長シグナルに関する簡潔な回答。
© 2026 Pubrio. 無断転載を禁じます。
